Mumbai, April 11 -- The move is aimed at strengthening Morepen's connect with doctors, pharmacies, patients, and healthcare professionals nationwide. It marks a bold step in scaling up the company's formulations business, which currently stands at around Rs 325 crore. Morepen has set its sights on building a Rs 1,000 crore finished dosages segment within the next five years.

To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production.

The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate...